Some interesting facts coming out of this or at least nicely...

Some interesting facts coming out of this or at least nicely documented and not sure if has been mentioned previously.

The white paper with the USyd business school looks like a good off-sided benefit for all cannabis companies in Australia, giving a value to potential medical cannabis market in Australia and provides a good talking point for the industry as a whole.

The assets liabilities ratio is looking good with $8million in cash with loss previous year of $6million so we have a decent amount of money to stretch us through the next financial year. That coupled with expected revenue from the derma product lines
"The Californian distribution deal’s first-year contract is worth approximately €1.2m and the Company expects further revenue uplift in the year ahead."